AstraZeneca (AZN) to Release Earnings on Thursday

AstraZeneca (NASDAQ:AZN - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 6th. Analysts expect AstraZeneca to post earnings of $1.10 per share and revenue of $14.19 billion for the quarter. Persons interested in registering for the company's conference call can do so using this link.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the company posted $0.87 earnings per share. The business's quarterly revenue was up 18.0% compared to the same quarter last year. On average, analysts expect AstraZeneca to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Price Performance

AZN stock traded up $0.97 during midday trading on Thursday, hitting $71.22. The company's stock had a trading volume of 2,692,730 shares, compared to its average volume of 4,758,627. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a 50 day moving average of $66.83 and a two-hundred day moving average of $73.99. The firm has a market capitalization of $220.84 billion, a price-to-earnings ratio of 34.07, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.